These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Prevention of potential delayed hemolytic transfusion reaction in two sickle cell patients using intravenous immunoglobulins and steroids before and after red blood cell exchange with antigen positive units and review literature. Shold J; Dasgupta A; Ye Z Transfus Apher Sci; 2024 Jun; 63(3):103920. PubMed ID: 38570214 [TBL] [Abstract][Full Text] [Related]
29. Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells. Irani MS; Karafin MS; Ernster L J Clin Apher; 2017 Feb; 32(1):59-61. PubMed ID: 27112240 [TBL] [Abstract][Full Text] [Related]
31. Cytokine changes in sickle-cell disease patients as markers predictive of the onset of delayed hemolytic transfusion reactions. Chadebech P; de Ménorval MA; Bodivit G; Jouard A; Pakdaman S; Lelong F; Habibi A; Galactéros F; Lecron JC; Pirenne F Cytokine; 2020 Dec; 136():155259. PubMed ID: 32920319 [TBL] [Abstract][Full Text] [Related]
32. [Two serial events of delayed hemolytic transfusion reactions due to different primary immune response-induced irregular antibodies]. Mizuno K; Yamazaki R; Uemura T; Koda Y; Kikuchi T; Mori T Rinsho Ketsueki; 2020; 61(10):1482-1486. PubMed ID: 33162444 [TBL] [Abstract][Full Text] [Related]
33. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228 [TBL] [Abstract][Full Text] [Related]
34. Release of mediators of systemic inflammatory response syndrome in the course of a severe delayed hemolytic transfusion reaction caused by anti-D. von Zabern I; Ehlers M; Grunwald U; Mauermann K; Greinacher A Transfusion; 1998 May; 38(5):459-68. PubMed ID: 9633559 [TBL] [Abstract][Full Text] [Related]
35. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Pirenne F; Yazdanbakhsh K Blood; 2018 Jun; 131(25):2773-2781. PubMed ID: 29724898 [TBL] [Abstract][Full Text] [Related]
36. Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange. Tormey CA; Stack G Arch Pathol Lab Med; 2013 Jun; 137(6):861-4. PubMed ID: 23721278 [TBL] [Abstract][Full Text] [Related]
37. An animal model for delayed hemolytic transfusion reactions. Ness PM; Shirey RS; Weinstein MH; King KE Transfus Med Rev; 2001 Oct; 15(4):305-17. PubMed ID: 11668437 [TBL] [Abstract][Full Text] [Related]
38. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Cullis JO; Win N; Dudley JM; Kaye T Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307 [TBL] [Abstract][Full Text] [Related]
39. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Roumenina LT; Bartolucci P; Pirenne F Transfus Med Rev; 2019 Oct; 33(4):225-230. PubMed ID: 31672341 [TBL] [Abstract][Full Text] [Related]
40. A delayed hemolytic transfusion reaction (DHTR) with multiple alloantibodies (Anti-E, Jka, Dia, Fyb, and S) induced by E-antigen-negative, crossmatch-compatible blood. Yamane K; Yagihashi A; Sasaki M; Kuwashima K; Morio A; Watanabe N Immunopharmacol Immunotoxicol; 1998 Nov; 20(4):531-9. PubMed ID: 9805232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]